<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03986944</url>
  </required_header>
  <id_info>
    <org_study_id>18-OBE2109-002</org_study_id>
    <nct_id>NCT03986944</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain</brief_title>
  <official_title>A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Assess the Efficacy and Safety of Linzagolix in Subjects With Moderate to Severe Endometriosis-associated Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ObsEva SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ObsEva SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the efficacy and safety of linzagolix
      administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in
      combination with add-back hormone replacement therapy (ABT: estradiol (E2) 1 mg /
      norethisterone acetate (NETA) 0.5 mg) versus placebo, in the management of moderate to severe
      endometriosis-associated pain (EAP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blind, placebo-controlled study to demonstrate the
      efficacy and safety of linzagolix administered orally once daily at doses of 75 mg alone and
      200 mg in combination with low dose ABT (E2 1 mg/NETA 0.5 mg) versus placebo in the
      management of moderate to severe EAP in 450 women.

      Eligible subjects who have completed the 6-month treatment period may enter a separate
      extension study for 6 additional months of active treatment (no placebo control). Subjects
      who do not continue in the extension study will enter a 6 month treatment-free follow-up
      phase.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dysmenorrhea</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Change at Month 3 from baseline in the mean daily assessment of dysmenorrhea measured on a Verbal Rating Scale (VRS) using an electronic diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-menstrual pelvic pain</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Change at Month 3 from baseline in the mean daily assessment of non-menstrual pelvic pain measured on a Verbal Rating Scale (VRS) using an electronic diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dysmenorrhea</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Change from baseline to Month 6 in dysmenorrhea measured on a Verbal Rating Scale (VRS) using an electronic diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-menstrual pelvic pain</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Change from baseline to Month 6 in non-menstrual pelvic pain measured on a Verbal Rating Scale (VRS) using an electronic diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyschezia</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Change from baseline to Month 6 in dyschezia measured on a Numeric Rating Scale (NRS) using an electronic diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Pelvic Pain</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Change from baseline to Month 6 in overall pelvic pain measured on a Numeric Rating Scale (NRS) using an electronic diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interference of pain with the ability to perform daily activities</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Change from baseline to Month 6 in the interference of pain with the ability to perform daily activities, measured using the pain dimension of the Endometriosis Health Profile-30 (EHP-30) using an electronic diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspareunia</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Change from baseline to Month 6 in dyspareunia measured on a Verbal Rating Scale (VRS) using an electronic diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No analgesic use for endometriosis associated pain</measure>
    <time_frame>During the preceding 4-week period at Month 6</time_frame>
    <description>Proportion of subjects reporting no analgesic use for endometriosis associated pain, during the preceding 4-week period at Month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No opiate use for endometriosis associated pain</measure>
    <time_frame>During the preceding 4-week period at Month 6</time_frame>
    <description>Proportion of subjects reporting no opiate use for endometriosis associated pain, during the preceding 4-week period at Month 6</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Add-back capsule (E2 1 mg / NETA 0.5 mg)</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet to match 75 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet to match 200 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule to match Add-back capsule</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        The subject must have:

          -  Her most recent surgical and - if available - histological diagnosis of pelvic
             endometriosis up to 10 years before screening.

          -  Moderate to severe endometriosis-associated pain during the screening period.

          -  Regular menstrual cycles.

          -  BMI â‰¥ 18 kg/m2 at the screening visit.

        Key Exclusion Criteria:

        The subject will be excluded if she:

          -  Is pregnant or breast feeding or is planning a pregnancy within the duration of the
             treatment period of the study.

          -  Is less than 6 months postpartum or 3 months postabortion/ miscarriage at the time of
             entry into the screening period.

          -  Has had a surgical history of any major abdominal surgery within 6 months or any
             interventional surgery for endometriosis performed within a period of 2 months before
             screening.

          -  Did not respond to prior treatment with GnRH agonists or GnRH antagonists for
             endometriosis.

          -  Has a history of, or known, osteoporosis or other metabolic bone disease.

          -  Has chronic pelvic pain that is not caused by endometriosis and requires chronic
             analgesic or other chronic therapy which would interfere with the assessment of
             endometriosis-associated pain.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females Only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lecomte</last_name>
    <role>Study Director</role>
    <affiliation>ObsEva SA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chief Medical Officer</last_name>
    <phone>+41 22 552 38 40</phone>
    <email>clinicaltrials@obseva.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Birmingham OBGYN / ID # 740</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesa Obstetricians and Gyneocologists / ID # 790</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Precision Trials AZ, LLC / ID # 783</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quality of LIfe Medical &amp; Research Center, LLC / ID # 813</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research-Tucson / ID # 754</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of the Ozarks / ID # 826</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas / ID # 735</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Join Clinical Trials / ID # 778</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Long Beach Clinical Trials, LLC / ID # 768</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Matrix Clinical Research / ID # 751</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Futura Research, Org / ID # 781</name>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <zip>90650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Institute / ID # 805</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Precision Research Institute / ID # 792</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Strategies Research Centers / ID # 765</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Downtown Women's Health Care / ID # 718</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Women's Health / ID # 817</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Center for Women's Health / ID # 761</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Physicians Research Options, LLC / Red Rocks Ob/Gyn / ID # 732</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gen1 Research / ID # 762</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine / ID # 806</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women's Health Partners, LLC. / ID # 745</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Dr. David I. Lubetkin, LLC / ID # 703</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helix Biomedics Clincial Research, LLC / ID # 750</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Research Group / ID # 721</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites, DeLand Clinical Research Unit / ID # 713</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universal Axon Clinical Research / ID # 769</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc. / ID # 773</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Florida Clinical Research Institute / ID # 747</name>
      <address>
        <city>Margate</city>
        <state>Florida</state>
        <zip>33063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Global Health Research Center, Inc. / ID # 787</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coral Way Research / ID # 799</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group, LLC / ID # 756</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Biotech Pharmaceutical Group LLC / ID # 786</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Salud Research Clinic, Inc. / ID # 824</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Associates, LLC / ID # 760</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LCC Medical Research Institute / ID # 814</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33196-1554</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sensible Healthcare / ID # 749</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A Premier Medical Research of Florida, LLC / ID # 752</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc. / ID # 731</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omega Research Orlando, LLC / ID # 785</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806-1133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Associates of Orlando, LLC / ID # 779</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. / ID # 725</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Physician Care Clinical Research LLC / ID # 810</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research, LLC / ID # 767</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida / ID # 738</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GCP Clinical Research, LLC / ID # 825</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgia Research for Women / ID # 759</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Women's Research Institute, Inc. / ID # 727</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sonara Clinical Research, LLC / ID # 720</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83646</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moore Health Wellness Research Institute, LLC / ID # 795</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providea Health Partners LLC / ID # 734</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC / ID # 784</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cypress Medical Research Center, LLC / ID # 755</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Horizon Research Group of Opelousas, LLC / ID # 757</name>
      <address>
        <city>Eunice</city>
        <state>Louisiana</state>
        <zip>70535-5100</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praetorian Pharmaceutical Research / ID # 739</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women Under Study, LLC / ID # 820</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University, School Of Medicine / ID # 816</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unified Women's Clinical Research / ID # 748</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Continental Clinical Solutions, LLC / ID # 777</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NECCR Fall River, LLC / Id # 712</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onyx Clinical Research / ID # 793</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CMEP/CMU health / ID # 812</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valley OBGYN / ID # 704</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saginaw Valley Medical Research Group, LLC / ID # 743</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Office of Edmond Pack, MD / Id # 818</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lawrence OB/GYN clinical Research, LLC / ID # 742</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocean Obstetric and Gynecology Associates / ID # 736</name>
      <address>
        <city>Ocean Township</city>
        <state>New Jersey</state>
        <zip>07712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials, Inc. / ID # 707</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center / ID # 758</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Institute for Clinical Research / ID # 728</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unified Women's Clinical Research - Green Valley OBGYN / ID # 719</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unified Women's Clinical Research - Morehead City Carteret OB-Gyn Associate / ID # 717</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Eastern Carolina Women's Center / Id # 794</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unified Women's Clinical Research - Raleigh / Id # 714</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Medical Trials, LLC / ID # 788</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals / ID # 808</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ClinOhio Research Services, LLC / ID # 722</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complete Healthcare for Women / ID # 801</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wright State Physicians / ID # 733</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hilltop OBGYN / ID # 711</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University / ID # 791</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OB/GYN Associates of Erie / ID # 706</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn State Health Milton S. Hershey Medical Center / ID # 804</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center / ID # 744</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VitaLink Research - Upstate / ID # 789</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of South Carolina / ID # 741</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center at Lowcountry Women's Specialists / ID # 776</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VitaLink Research Spartanburg / ID # 753</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seasons at Bristol / ID # 705</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>WR-ClinSearch, LLC / ID # 821</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center / ID # 780</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc / ID # 772</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates Inc / ID # 802</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Area ObGyn PLLC / ID # 701</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christina Sebestyen MD, P.A. dba OBGYN North / ID # 764</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christus St. Elizabeth Gadolin Research, LLC / ID # 774</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HCWC dba DiscoveryClinical Trials / ID # 771</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center / ID # 823</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Signature Gyn Services / ID # 726</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group / ID # 763</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown OB/GYN / ID # 770</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group, LLC / ID # 729</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vilo Research Group / ID # 709</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TMC Life Research, Inc. / ID # 809</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Las Colinas Obstetrics, Gynecology and Infertility Associates, PA / ID # 724</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Colleagues of Texas / ID # 819</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FMC Science / ID # 730</name>
      <address>
        <city>Lampasas</city>
        <state>Texas</state>
        <zip>76550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maximos OB/GYN / ID # 737</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DCT-McAllen Primary Care Research, LLC dba Discovery Clinical Trials / ID # 803</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DCT-AACT, LLC dba Discovery Clinical Trials / ID # 815</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group, LLC / ID # 798</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research of San Antonio, LLC / ID # 710</name>
      <address>
        <city>Schertz</city>
        <state>Texas</state>
        <zip>78154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Physicians Research Options PRO / ID # 766</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Old Farm Obstetrics and Gynecology/Advanced Clinical Research / ID # 782</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research / ID # 746</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Highland Clinical Research / ID # 708</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners, LLC / ID # 715</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners, LLC / ID # 775</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tidewater Clinical Research The Group for Women / ID # 716</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center / ID # 723</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Women's: Health, Research, Gynecology / ID # 702</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Reproductive Medicine / ID # 811</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CARe Clinic / ID # 872</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <zip>T4N 6V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Centre / ID # 870</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital / ID # 874</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Victory Reproductive Care / ID # 873</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8N C52</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ponce Medical SChool Foundation Inc./ CAIMED Center / ID # 891</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Puerto Rico Medical Research Inc. / ID # 890</name>
      <address>
        <city>Ponce</city>
        <zip>00717</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dysmenorrhea</keyword>
  <keyword>Dyspareunia</keyword>
  <keyword>Dyschezia</keyword>
  <keyword>Non-menstrual pelvic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

